Neutrophils from patients with SAPHO syndrome show no signs of aberrant NADPH oxidase-dependent production of intracellular reactive oxygen species

Per Wekell1,2,*, Halla Björnsdottir3,*, Lena Björkman3, Martina Sundqvist3, Karin Christenson3, Veronica Osla3, Stefan Berg2,4, Anders Fasth2,4, Amanda Welin3, Johan Bylund5,1 and Anna Karlsson3,1

Abstract

Objective. We aimed to investigate if aberrant intracellular production of NADPH oxidase-derived reactive oxygen species (ROS) in neutrophils is a disease mechanism in the autoinflammatory disease SAPHO syndrome, characterized by synovitis, acne, pustulosis, hyperostosis and osteitis, as has previously been suggested based on a family with SAPHO syndrome-like disease.

Methods. Neutrophil function was explored in a cohort of four patients with SAPHO syndrome, two of whom were sampled during both inflammatory and non-inflammatory phase. Intracellular neutrophil ROS production was determined by luminol-amplified chemiluminescence in response to phorbol myristate acetate.

Results. Cells from all patients produced normal amounts of ROS, both intra- and extracellularly, when compared with internal controls as well as with a large collection of healthy controls assayed in the laboratory over time (showing an extensive inter-personal variability in a normal population). Further, intracellular production of ROS increased during the inflammatory phase. Neutrophil activation markers were comparable between patients and controls.

Conclusion. Dysfunctional generation of intracellular ROS in neutrophils is not a generalizable feature in SAPHO syndrome. Secondly, serum amyloid A appears to be a more sensitive inflammatory marker than CRP during improvement and relapses in SAPHO syndrome.

Key words: NADPH oxidase, SAPHO syndrome, granulocytes, reactive oxygen species, autoinflammation, inflammation

---

Rheumatology key messages

- The SAPHO syndrome is not by necessity associated with deficient neutrophil intracellular reactive oxygen species production.
- Neutrophils from patients with SAPHO syndrome are pre-primed in circulation during an inflammatory phase.
- Serum amyloid A is a more sensitive marker than CRP during SAPHO syndrome improvement and relapse.

Submitted 10 May 2015; revised version accepted 8 March 2016

*Per Wekell and Halla Björnsdottir contributed equally to this study.
†Johan Bylund and Anna Karlsson contributed equally to this study.

Correspondence to: Anna Karlsson, Department of Rheumatology and Inflammation Research, University of Gothenburg, Box 480, SE-405 30 Gothenburg, Sweden. E-mail anna.karlsson@rheuma.gu.se

© The Author 2016. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

SAPHO syndrome, characterized by synovitis, acne, pustulosis, hyperostosis and osteitis, was first described as a clinical entity in 1987 by Chamot et al. [1]. It is classified among the autoinflammatory diseases, defined by Kastner as ‘abnormally increased inflammation, mediated predominantly by cells and molecules of the innate immune system, with a significant host predisposition’ [2]. More specifically, SAPHO syndrome belongs to the autoinflammatory bone disorders, in which dysregulation of innate immunity causes inflammation in sterile bone [3–5]. Autoinflammatory bone disorders also include chronic recurrent multifocal osteomyelitis, chronic non-bacterial osteomyelitis and Majeed syndrome [3–8]. It remains to be clarified how these diseases differ from each other [3, 5].

The bone lesions observed in SAPHO syndrome represent a clinical spectrum from self-limiting single- or oligo-lesions to chronic lesion(s) or recurrent multifocal osteomyelitis. The histopathology of the lesions mimics infectious osteomyelitis but the lesions are typically sterile [9]. Skin lesions in SAPHO syndrome are characterized by neutrophil dermatosis, that is, severe acne, palmoplantar pustulosis and psoriasis [1, 10, 11].

Autoinflammatory diseases are by definition mediated by innate immune cells. There is growing evidence of neutrophil dysfunction in human inflammatory disorders [12–19], but their specific role in disease pathology remains largely unknown. In a study by Ferguson et al. [13], the function of neutrophils was investigated in a mother and daughter affected by a SAPHO syndrome-like disease. The major finding was that the patients’ cells displayed aberrant production of nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase-derived reactive oxygen species (ROS), but the biological significance of this finding was not clarified.

ROS production is a prominent neutrophil feature, contributing to, for example, antimicrobial defence. The enzyme responsible for ROS production, the NAPDH oxidase, is an electron-transport system that when assembled in a membrane reduces oxygen to superoxide anion, subsequently forming other ROS. NAPDH oxidase assembly can occur at the plasma membrane, resulting in release of ROS extracellularly or into a phagosome. The NAPDH oxidase can also assemble at intracellular membranes, giving rise to intracellular ROS production localized in the phagolysosome as well as in non-phagosomal granules (intragranular ROS) [20].

The function of intragranular ROS is not fully understood, but they are thought to be involved in subcellular signalling events. A specific deficiency in intracellular ROS production has been linked to hyperinflammatory conditions in a novel form (p40<sup>shmo</sup>) of chronic granulomatous disease [21]. Along the same lines, the study by Ferguson et al. [13] showed that intracellular ROS production was defective in neutrophils from the patients with SAPHO syndrome-like disease, which also displayed a hyperinflammatory phenotype [13].

To follow up on the study by Ferguson et al., we explored neutrophil ROS production in a small cohort of four patients with SAPHO syndrome. We found that neutrophils from these patients produced normal amounts of ROS, both intra- and extracellularly, and that the cells behaved similarly to control neutrophils when assayed in vitro. Our data thus demonstrate that aberrant generation of intracellular ROS in neutrophils is not a generalizable feature in SAPHO syndrome.

Patients and methods

Patients

Three diagnostic criteria for SAPHO syndrome, of which one is sufficient for diagnosis, were proposed by Kahn and Kahn in 1994: chronic recurrent multifocal osteomyelitis with or without skin manifestation; acute or chronic sterile arthritis associated with pustular psoriasis, palmoplantar pustulosis or severe acne; and sterile osteitis in the presence of one of the skin manifestations [22]. We included four patients diagnosed with SAPHO syndrome according to the third criterion. A summary of clinical features and investigations of included patients is given in Table 1 and detailed clinical descriptions and disease history for the patients are given in supplementary data, available at Rheumatology Online. When attempting to investigate whether a mechanistic feature is generalizable for all patients diagnosed with a disease (such as SAPHO syndrome), it is an advantage to include patients from different subcohorts, that is, of different ages, presentation and treatment approaches but all falling within the disease criteria. Therefore we found it valuable to investigate patients suffering from SAPHO syndrome who were quite different from one another, despite their constituting a relatively small cohort.

In short, patient A (age at onset, 15 years; previously healthy; male) with severe acne was brought to the hospital with pain in the right knee and fever. He was diagnosed with SAPHO and after that MRI and bone scan showed multiple lesions in knees, trochanter major, foot and clavicle compatible with osteomyelitis. He received long-term treatment with ibuprofen and was asymptomatic with normal inflammatory marker after 2.5 months of treatment.

Patient B (age at onset, 15 years; previously healthy; male) with acne fulminant was referred to the hospital with fever and pain from multiple locations. MRI and bone scan revealed multiple bone lesions compatible with osteomyelitis in sacrum, sternocostal joint, corpus sternum and vertebral bodies. The patient was diagnosed with SAPHO syndrome and treated with prednisone, MTX and NSAID. He was free of symptom with normal inflammatory markers after 6 months, but relapsed after 2 years.

Patient C (68 years old; female; with non-erosive PsA) was diagnosed with SAPHO syndrome based on palmoplantar pustulosis, osteosclerotic lesions, hyperostosis and arthritis of the sternocostal joint. Treatment with MTX (20 mg/week) was initiated and treatment outcome has yet to be evaluated.

Patient D (56 years old; female; with PsA) was diagnosed with SAPHO syndrome based on pustulosis.
TABLE 1 Clinical features and investigations of included patients

| Parameter | Patient A | Patient B | Patient C | Patient D |
|-----------|-----------|-----------|-----------|-----------|
| Gender    | Male      | Male      | Female    | Female    |
| Age at onset, years | 15 | 15 | Not known | 45 |
| Presenting symptom | Fever; right knee pain | Fever; hip, wrist and thorax pain | Thorax, back and shoulder pain | Synovitis of sternocostal joint; hip and wrist pain |
| Skin findings | Cystic acne | Acne fulminans | Pustulosis palmoplantaris | Pustulosis palmoplantaris |
| Location of bone lesions on bone scan and/or MRI | Both knees, right trochanter major, left foot and left medial clavicle | Left sacrum, right sternocostal joint, corpus sternum, Th7, Th8 and Th9 | Left sacrum, right sternocostal joint, corpus sternum, Th7, Th8 and Th9 | Bilateral sternocostal and sacroiliac joints |
| CRP at admission, mg/l | 160 | 84 | <5 | -5 |
| ESR, mm/h | 95 | 115 | 34 | -20 |
| Blood culture | Negative × 2 | Negative × 2 | Negative | Negative |
| Biopsy histology | Normal tissue | No signs of malignancy, inflammation or infection | Normal | Normal |
| Biopsy culture | Staphylococcus hominis | Streptococcus miliaris | NP | NP |
| Biopsy 16S rRNA | Negative | NP | NP | NP |
| Duration first episode (onset to asymptomatic) | 2.5 months | 6 months | Still symptomatic, recently started antinflammatory treatment | 3 months |
| Treatment, duration | Ioxacillin IV (9 d) NSAID (1 y) Amoxicillin (6 w) | Cefotaxime IV (13 d) NSAID (1 y) Prednisone (3 w) Ioxacillin (6 w) Omeprazol (3 w) MTX (1 y) | | Infliximab (15 months) |
| Follow-up time | 2 years | 3 years | 1 month | 2.5 years |
| Number of episodes | 1 | 2 | First episode ongoing | 1 |

*aTc-99m HDP bone scintigraphy. **Duration given in d, w, mo or y; years; mo: month; w: weeks; d: days. NP: not performed.
palmoplantaris and hyperostosis of sternocostal joints. Treatment with infliximab resulted in remission and is continued on a monthly basis.

**Complete blood cell count, acute phase reactants and cytokine measurements**

Complete blood cell count and white blood cell differential were determined using an ADVIA cell counter (ADVIA, Siemens Healthcare, Erlangen, Germany). Acute phase proteins (CRP; serum amyloid A, SAA) were measured in serum by ELISA. Inflammatory cytokines were measured in plasma by Bio-Plex Pro Human Cytokine Group I 10-Plex Assay and Bio-Plex Manager Software (Bio-Rad Laboratories, Hercules, CA, USA).

**Blood sampling of patients and definition of inflammatory/non-inflammatory patient status**

Patients A and B were followed with CRP and SAA levels in serum over time as part of routine care (Fig. 1). At two time-points, corresponding to an inflammatory phase (defined by increased CRP and SAA, Table 2; samples A1 and B1) and a non-inflammatory phase (defined by normalized CRP and SAA, Table 2; samples A2 and B2), heparinized venous blood and plasma was collected (see below) for analysis of neutrophil function and cytokine levels, respectively (Fig. 1). The sample from patient C was collected during an inflammatory phase (slightly elevated CRP) while patient D was under treatment with an anti-TNFα inhibitor (infliximab) and was non-inflammatory at time of sampling. Samples from adult controls were analysed in parallel.

The inflammatory status of patients A and B was confirmed by complete blood cell counts and white blood cell differentials (Table 2), showing that the absolute numbers of neutrophils, monocytes and thrombocytes were increased during the inflammatory phase as compared with the non-inflammatory phase, although the absolute numbers of neutrophils and monocytes were within the normal range (Table 2). For patients C and D, the blood cell counts were within the normal range (Table 2).

The inflammatory status of patients A and B at the first sampling was supported by plasma cytokine levels; patient A showed high amounts of IL-6 (but no other cytokines) and patient B displayed an increase in IL-6, IL-12, IFN-γ and GM-CSF (supplementary Fig. S1, available at Rheumatology Online). Both patients were within normal range of cytokines at the second sampling (non-inflammatory phase). Samples from patients C and D were not analysed for plasma cytokines.

**Control samples**

Each patient sample was processed and analysed in parallel with a control sample. These samples were collected from healthy adult blood donors from the Sahlgrenska University Hospital Blood Centre, Gothenburg. We did not use age-matched controls for the adolescent patients A and B, as such controls could not be obtained for parallel analysis of cell function. In addition, the patient data were compared with a compiled set of control data from healthy adult blood donors collected over time in our laboratory, comparing cytokine content in plasma (n = 11–20) and neutrophil production of ROS (n = 29).

**Neutrophil isolation**

Peripheral blood neutrophils were isolated according to Böyum et al. [23]. After isolation, neutrophils were suspended in Krebs-Ringer glucose (KRG) buffer supplemented with Ca²⁺ (KRG-Ca; 1 mM), and stored on ice.

**ROS production measured by luminol-/isoluminol-enhanced chemiluminescence**

NADPH oxidase-derived ROS production was measured using luminol-/isoluminol-enhanced chemiluminescence (CL) [24]. Extracellular ROS was measured in the presence of isoluminol (56 μM; Sigma-Aldrich, St Louis, MO, USA; membrane-impermeable) and horseradish peroxidase (4 U/ml) while intracellular ROS was measured in the presence of luminol (56 μM; Sigma-Aldrich; membrane-permeable), and the extracellular ROS scavengers superoxide dismutase (50 U/ml; Worthington Biochemical Corp., Lakewood, NJ, USA).
Neutrophil NADPH oxidase activity in SAPHO

Table 2. Laboratory variables in blood samples from SAPHO syndrome patients during an inflammatory (A1, B1 and C) or a symptom-free (A2, B2 and D) phase

| Patient | CRP, mg/l | SAA, mg/l | Hb, g/l | Platelets, x 10^9/l | WBC, x 10^9/l | ANC, x 10^9/l | ALC, x 10^9/l | AMC, x 10^9/l | AEC, x 10^9/l | ABC, x 10^9/l |
|---------|-----------|-----------|--------|---------------------|---------------|---------------|---------------|---------------|---------------|--------------|
| A1      | <5        | >600      | 122    | 476                 | 6.4           | 4.3           | 1.6           | 0.35          | 0.18          | 0.03         |
| A2      | >5        | >11       | 145    | 268                 | 3.6           | 1.9           | 1.3           | 0.22          | 0.15          | 0.02         |
| B1      | >5        | >11       | 137    | 385                 | 10.7          | 7.1           | 2.8           | 0.70          | 0.06          | 0.03         |
| B2      | >5        | >11       | 141    | 275                 | 5.7           | 2.3           | 3.0           | 0.41          | 0.04          | 0.02         |
| C       | 9         | —         | 110    | 349                 | 9.7           | —             | —             | —             | —             |
| D       | <5        | 120       | 115    | 314                 | 7.8           | —             | —             | —             | —             |
| Normal  | <5        | 130-160   | 150-350| 4.5-15              | 1.5-8.5       | 2.9-9.5       | 0.1-1         | 0.04-0.4      | 0.0-0.1       |

ABC: absolute basophil count; AEC: absolute eosinophil count; ALC: absolute lymphocyte count; AMC: absolute monocyte count; ANC: absolute neutrophil count; Hb: haemoglobin; SAA: serum amyloid A; WBC: white blood cell count.

USA) and catalase (2000 U/ml; Worthington) [25]. Neutrophils (5 x 10⁶ cells/ml) and reagents were incubated in KRG-Ca for 5 min at 37 °C before stimulation with the protein kinase C activator phorbol myristate acetate (PMA; 5 x 10⁻⁸ M; Sigma-Aldrich). The CL activity was measured continuously in a six-channel Biolumat LB 9505 (Berthold Technologies, Zug, Switzerland) or Mithras LB 940 CL (Berthold Technologies) for 20 min and peak CL values were used for comparison between samples.

Hydrogen peroxide production measured with p-hydroxyphenylacetic acid

Hydrogen peroxide production was measured as oxidation of p-hydroxyphenylacetic acid (PHPA) [24]. Neutrophils (7.5 x 10⁵) were incubated in KRG-Ca with PHPA (3.3 mM; Sigma-Aldrich) and horseradish peroxidase (4 U/ml, Roche, Mannheim, Germany) at 37 °C and stimulated with PMA (5 x 10⁻⁸ M) after which PHPA oxidation was measured over time in a fluorometer (Perkin Elmer, Waltham, MA, USA) (excitation/emission wavelengths 317/400 nm). The PHPA molecule is membrane-impermeant, thus extracellular hydrogen peroxide was exclusively measured. The total amount of hydrogen peroxide (intracellular plus extracellular) was measured in the presence of azide (1 mM), which inhibits intracellular consumption of ROS [24] and allows for intracellular hydrogen peroxide to leak out of the cell and be measured extracellularly. Intracellular hydrogen peroxide production was calculated as total minus extracellular hydrogen peroxide production. The results show the accumulated PHPA fluorescence after 15 min stimulation.

Myeloperoxidase quantification assay

Neutrophils (10⁶ cells/ml) were lysed with Triton X-100 (0.1%; Merck, Darmstadt, Germany) for 10 min at 4 °C after which the samples were centrifuged for 15 s at 16100g. Myeloperoxidase (MPO) content in the cell homogenates was measured by ELISA (Novakemi).

Neutrophil activation assays

Uptregulation of CD35 (complement receptor 1) and CD11b (α-chain of CR3) on the cell surface as well as shedding of CD62L (L-selectin) were used as neutrophil activation markers. Peripheral blood was left untreated at room temperature or incubated for 20 min at 37 °C with or without TNFα (10 ng/ml; a neutrophil secretagogue; Sigma-Aldrich). Leucocytes were fixated and erythrocytes lysed with FACS lysing solution (BD) for 15 min at 4 °C. Leucocytes were then stained with phycoerythrin-conjugated anti-CD35 (BD Biosciences, Franklin Lakes, NJ, USA), anti-CD11b (BD) or anti-CD66L (BD) antibodies for 1 h on ice. The cells were washed in PBS and a minimum of 10 000 neutrophils (gated on basis of forward and side scatter) was analysed by flow cytometry (BD Accuri C6 and FlowJo software).

Evaluation of apoptosis

Neutrophil cell death was monitored essentially as described earlier [26]. Cells (5 x 10⁶ cells/ml) were suspended in RPMI 1640 medium with 10% heat-inactivated fetal calf serum and 1% penicillin/streptomycin (PAA Laboratories GmbH, Pasching, Austria) and incubated at 37 °C in 5% CO₂ in the absence or presence of anti-CD95 monoclonal antibody (Fas ligand; pro-apoptotic stimulus; Nordic Biosite, Täby, Sweden) or lipopolysaccharide (LPS; anti-apoptotic stimulus; Sigma-Aldrich). After 20 h incubation the cells were stained with Annexin V-FLUOS (for apoptosis; Roche) and 7-aminoactinomycin D (for necrosis; BD). A minimum of 10 000 neutrophils were analysed by flow cytometry.

Ethics statement

The children were enrolled and received care at the Pediatric Department, NU-Hospital Group in Trollhättan and Uddevalla, in consultation with pediatric rheumatologists at the Queen Silvia Children’s Hospital, Gothenburg. The adult patients were enrolled at the Department of Rheumatology, Sahlgrenska University Hospital, Gothenburg. Informed consent from patients and parents was obtained in accordance with the Declaration of Helsinki. The Regional Ethical Review Board, Gothenburg, Sweden, approved the study.

www.rheumatology.oxfordjournals.org
Results

Neutrophils from patients with SAPHO syndrome have normal extra- and intracellular ROS production capacity

Neutrophil NADPH oxidase activity was investigated using the isoluminol/luminol CL system that can be used to distinguish between extra- and intracellular ROS production. Neutrophils from patients with SAPHO syndrome responded to PMA stimulation with ROS production both extracellularly (Fig. 2A) and intracellularly (Fig. 2B). All samples showed ROS production that was within normal range (samples C and D, data not shown) as compared with CL activity in internal controls as well as compiled data from healthy donors (Fig. 2A and B; samples C and D, data not shown). Notably, both patients A and B produced more both extra- and intracellular ROS when they were in an inflammatory state (A1 and B1) compared with a later time point when the inflammation had resolved (A2 and B2; Fig. 2A and B).

Intracellular ROS production was also investigated by the PHPA method. In line with the CL results, neutrophils from patients with SAPHO syndrome produced similar amounts of both extra- and intracellular hydrogen peroxide in response to PMA, as compared with control cells (Fig. 2C; samples C and D, data not shown). Taken together, neutrophil ROS production was normal in our cohort of patients with SAPHO syndrome, both during an inflammatory flare and after resolution of inflammation.

Determination of intracellular ROS using luminol-amplified CL is MPO-dependent [24]. We therefore quantified MPO in neutrophil lysates to ensure that altered MPO levels did not influence the CL results. We found similar amounts of MPO in controls and patients (Fig. 2D and data not shown).

Neutrophils from patients with SAPHO syndrome can be primed and show normal receptor upregulation and shedding

In circulation, neutrophils are in a quiescent state. After transmigration from the vessels into the (inflamed) tissue, neutrophils become primed, that is, increasingly responsive to inflammatory stimuli. This is in part achieved by mobilization of intracellular granules to the cell surface, leading to increased receptor exposure (CD35 and CD11b) and shedding of cell-to-cell interaction molecules (CD62L) involved in transendothelial migration [27]. Primed neutrophils are normally not found in circulation, but can be present under certain infectious or aseptic inflammatory conditions [14, 17, 28–30].

Receptor exposure was measured on neutrophils in blood to investigate whether cells from patients with SAPHO syndrome had a primed phenotype. The cell surface markers CD35, CD11b and CD62L were measured in neutrophils from blood kept at room temperature or at 37 °C without or with the priming agent TNFα. There were no major differences in basal levels of CD11b, CD35 or CD62L on any of the patient neutrophils as compared with control neutrophils (data not shown). Incubation of the cells from patients A and B at 37 °C in the absence of TNF did not substantially affect the levels of CD11b and CD35, but after TNF stimulation these granule markers had significantly increased on the cell surface (Fig. 3A and B), in line with the results on control cells.
Correspondingly, the cleavage of CD62L was primarily seen after TNF treatment of the neutrophils, and to similar extents as for the controls (Fig. 3C). Taken together, these data show that neutrophils from patients with SAPHO syndrome show no alterations in responsiveness to priming agents, and have a normal degranulation function.

Nevertheless, neutrophils in the inflammatory sample from patient A (A1) showed slightly increased CD11b after incubation at 37 °C and a corresponding cleavage of CD62L (Fig. 3). Also patient C showed upregulation of neutrophil CD11b as compared with control cells (data not shown) in the 37 °C sample, in line with the inflammatory status of this patient (Table 2). These data suggest that an inflammatory episode of SAPHO syndrome can be associated with the neutrophils taking on a pre-primed phenotype.

Neutrophils from patient C responded well to TNF-α priming (data not shown), that is, the priming mechanisms were intact in these cells as for patients A and B. Neutrophils from patient D, however, did not respond to TNF-α priming in vitro (data not shown). Since this patient was on anti-TNF-α treatment at the time of sampling, and the assay was done in whole blood and not with isolated white blood cells, we believe that the presence of TNF inhibition therapy affected the neutrophil responsiveness to TNF-α.

Neutrophil apoptosis in SAPHO syndrome

Neutrophils are short-lived cells and spontaneous apoptosis is of importance to maintain homeostasis. Under inflammatory conditions the longevity of neutrophils has been reported to increase [14, 19] or decrease [31–33]. We tested whether the neutrophils from patients with SAPHO syndrome showed any tendencies of altered apoptosis in a 20 h in vitro assay. Spontaneous apoptosis was lower in the inflammatory neutrophil sample from patient B (Fig. 4, B1), in accordance with the highly inflammatory status of this patient [30, 31]. The neutrophils in this sample responded readily to pro-apoptotic (FASL) and anti-apoptotic stimuli (LPS) (Fig. 4), indicating normal apoptosis regulation. Neutrophils from patient A (Fig. 4) showed normal spontaneous apoptosis and responded to the anti-apoptotic stimulus LPS, although this effect was slightly less apparent in these cells compared with controls. The pro-apoptotic effect induced by FASL in these samples, as well as in sample B2, was very low, most probably due to the already quite high spontaneous apoptosis in these samples after 20 h incubation. Patients C and D showed normal apoptosis regulation.

Isolated neutrophils were incubated for 20 h in vitro in the absence (buffer; spontaneous apoptosis) or presence of FASL (pro-apoptotic stimulus) or LPS (anti-apoptotic stimulus). The cells were then stained with Annexin V and 7AAD, and analysed by flow cytometry to investigate the level of apoptosis (Annexin V positive, 7AAD negative). The graph shows the percentage of apoptotic neutrophils in the different samples. The controls (n = 4) are shown as means and SD.

Neutrophil apoptosis in SAPHO syndrome

Neutrophils are short-lived cells and spontaneous apoptosis is of importance to maintain homeostasis. Under inflammatory conditions the longevity of neutrophils has been reported to increase [14, 19] or decrease [31–33]. We tested whether the neutrophils from patients with SAPHO syndrome showed any tendencies of altered apoptosis in a 20 h in vitro assay. Spontaneous apoptosis was lower in the inflammatory neutrophil sample from patient B (Fig. 4, B1), in accordance with the highly inflammatory status of this patient [30, 31]. The neutrophils in this sample responded readily to pro-apoptotic (FASL) and anti-apoptotic stimuli (LPS) (Fig. 4), indicating normal apoptosis regulation. Neutrophils from patient A (Fig. 4) showed normal spontaneous apoptosis and responded to the anti-apoptotic stimulus LPS, although this effect was slightly less apparent in these cells compared with controls. The pro-apoptotic effect induced by FASL in these samples, as well as in sample B2, was very low, most probably due to the already quite high spontaneous apoptosis in these samples after 20 h incubation. Patients C and D showed normal apoptosis regulation.
(data not shown). Taken together no signs of dysregulated neutrophil apoptosis could be associated with SAPHO syndrome.

SAA is a more sensitive inflammation marker than CRP during resolution and relapse in SAPHO syndrome

For patients A and B, both SAA and CRP were markedly increased during the acute onset of disease (Fig. 1). Interestingly, SAA was consistently higher during the follow-up period and began the decrease back to baseline at a later time point than CRP in both patients. During relapse in patient B, SAA increased earlier and rose substantially more than CRP (Fig. 1B). In addition, patient D, who was in remission at the time of sampling, showed increased SAA levels. As she was sampled 5 weeks after infliximab treatment and just prior to receiving the next dose, we anticipate that SAA could be a sign of reactivation of the inflammatory response. Thus, SAA can be considered a more sensitive monitoring acute-phase reactant in these patients as compared with CRP, the more widely used inflammation marker.

Discussion

The inflammatory mechanisms underlying SAPHO syndrome are largely unknown, but neutrophil activation is suggested as part of disease pathophysiology [34]. The interesting study by Ferguson and co-workers [13] investigating a family with SAPHO syndrome-like phenotype, featuring pustulosis, severe acne and osteitis, has fostered an intense discussion regarding the pathogenesis of SAPHO syndrome [22, 35, 36]. A main finding of that study was that intracellular ROS production was defective in the patient neutrophils, suggesting that this feature is associated with the hyperinflammatory phenotype of SAPHO syndrome. Specific lack of intracellular ROS production has also been linked with atypical chronic granulomatous disease [21], featuring hyperinflammation. Both these findings indicate a regulatory role for intracellular ROS in aseptic inflammation.

The generalizability of decreased intracellular neutrophil ROS production as part of SAPHO syndrome pathogenesis has so far not been investigated, which is why we analysed four patients diagnosed with the disease, with involvement of both bone and skin. We chose to include patients of relatively different characteristics, but within the diagnostic boundaries. In this small cohort, we were, however, unable to verify the neutrophil phenotype presented by Ferguson and coworkers; intracellular ROS production was normal in neutrophils from all patients in our cohort. Not only did the patient neutrophils produce normal levels of intracellular ROS, but the intracellular ROS production was also increased during inflammatory periods as compared with periods of remission in both patients for whom such samples were available. In fact, this is in accordance with our recently published data on patients with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome [30]. Neutrophils from patients with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis produced increased amounts of intracellular ROS during fever flares compared with periods of remission, suggesting that increased intracellular ROS is associated with the proinflammatory episodes also of that disease. Whether this is a generalizable effect in autoinflammatory disease, now supported by our findings in SAPHO patients, remains to be investigated.

The inter-individual variation in neutrophil ROS production is in our experience quite large and the use of one or two paired controls for comparison with a patient sample, as employed in many studies, can be misleading when drawing conclusions on results being out of range. We therefore compiled a larger set of control data from analyses done in our laboratory over time, for comparison with the SAPHO syndrome samples (and their paired controls). The data showed considerable inter-individual variability (Fig. 2), and compared with this large control cohort, neutrophils from all patients generated normal levels of ROS, both intra- and extracellularly and at all sampling occasions. However, we can draw the conclusion that patients A and B vary in their ROS production between the two sampling times (inflammatory and non-inflammatory phase), as interindividual variation in neutrophil ROS production is low (A. Karlsson and J. Bylund, unpublished data).

We also performed a general characterization of neutrophil function in the SAPHO syndrome cohort. Neutrophils exist in different priming and activation states depending on the inflammatory status of their milieu. Priming of neutrophils is mainly due to upregulation of new receptors such as CD35 and CD11b from intracellular granule stores, but is also accompanied by shedding of CD62L from the surface. This process renders the cells more responsive to inflammatory stimuli when needed, but leaves the cells inactive, and thus less dangerous to their immediate surroundings. The priming process involves phenotypic changes such as decreased spontaneous apoptosis [37] and altered expression of surface receptors [38]. In neutrophils from patients with SAPHO syndrome, the responsiveness to the priming stimulus TNF seen as degranulation-dependent receptor upregulation and CD62L shedding was normal, as was the regulation of apoptosis in response to pro- and anti-apoptotic stimulation. We found neutrophils from two of the patients in an inflammatory phase of SAPHO syndrome to be slightly more easily primed than healthy controls (and patient samples taken in the non-inflammatory phase), that is, they were pre-primed. The presence of such pre-primed neutrophils in peripheral blood could possibly increase the risk for unnecessary inflammatory activation, as they are more easily triggered and may be activated prematurely, in the wrong place at the wrong time.

Finally, SAA appeared to be a more sensitive biomarker during SAPHO syndrome improvement and relapse. In fact, SAA was significantly elevated on several occasions when CRP was normal. We therefore suggest that SAA may be a valuable inflammatory indicator for monitoring disease progression and treatment response in SAPHO syndrome, in particular during circumstances where CRP is only slightly (or not at all) increased.
Taken together, neutrophils from patients with SAPHO syndrome showed a normal neutrophil phenotype with regard to functional parameters such as ROS production, degranulation, priming and apoptosis regulation. We conclude that a deficient NADPH oxidase-dependent ROS production in neutrophils is not a general feature associated with SAPHO syndrome, as has previously been suggested, and the pathological mechanisms behind this disease are still a matter of uncertainty.

Acknowledgements

The authors thank participating patients and families. We also acknowledge the physicians and nurses providing clinical care of the patients, in particular Drs Eva Karnä, Ann Olsson, Karin Rydenman and Håkan Östberg. We thank Eva Olsson for coordination of the clinical aspects of the study and for providing logistic support.

Funding: This work was supported by the Swedish Medical Research Council, the Swedish Rheumatism Foundation, the King Gustaf V 80-year Memorial Foundation, the Fyrbodal Research and Development Council, Region Västra Götaland, the Department of Research and Development NU-Hospital Organisation, the Clas Groschinsky Foundation and the Swedish government under the agreement concerning research and education of physicians (ALF).

Disclosure statement: The authors have declared no conflicts of interest.

Supplementary data

Supplementary data are available at Rheumatology Online.

References

1 Chamot AM, Benhamou CL, Kahn MF et al. [Acne-pustulosis-hyperostosis-ostitis syndrome. Results of a national survey. 85 cases]. Rev Rhum Mal Osteoartic 1987;54:187–96.
2 Kastner DL, Akseintjievich I, Goldbach-Mansky R. Autoinflammatory disease reloaded: a clinical perspective. Cell 2010;140:784–90.
3 Hedrich CM, Hofmann SR, Pablik J, Morbach H, Girschick HJ. Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatric Rheumatol Online J 2013;11:47.
4 Morbach H, Hedrich CM, Beer M, Girschick HJ. Autoinflammatory bone disorders. Clin Immunol 2013;147:185–96.
5 Stern SM, Ferguson PJ. Autoinflammatory bone diseases. Rheum Dis Clinics North Am 2013;39:735–49.
6 Ferguson PJ, El-Shanti HI. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007;19:492–8.
7 Grateau G, Hentgen V, Stojanovic KS et al. How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol 2013;9:624–9.
8 Masters SL, Simon A, Akseintjievich I, Kastner DL. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Ann Rev Immunol 2009;27:621–68.
9 Sharma M, Ferguson PJ. Autoinflammatory bone disorders: update on immunologic abnormalities and clues about possible triggers. Curr Opin Rheumatol 2013;25:658–64.
10 Benhamou CL, Chamot AM, Kahn MF. Synovitis-acne-pustulosis hyperostosis-osteomyelitis syndrome (SAPHO). A new syndrome among the spondyloarthropathies? Clin Exp Rheumatol 1988;6:109–12.
11 Beretta-Piccoli BC, Sauvain MJ, Gai I et al. Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature. Eur J Pediatrics 2000;159:594–601.
12 Anton PA, Targan SR, Vigna SR et al. Enhanced neutrophil chemiluminescence in familial Mediterranean fever. J Clin Immunol 1988;8:148–56.
13 Ferguson PJ, Lokuta MA, El-Shanti HI et al. Neutrophil dysfunction in a family with a SAPHO syndrome-like phenotype. Arthritis Rheum 2008;58:3264–9.
14 Harper L, Cockwell P, Adu D, Savage CO. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 2001;59:1729–38.
15 Midgley A, McLaren Z, Moots RJ, Edwards SW, Beresford MW. The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2009;60:2390–401.
16 Molaïd Y, Friidenberg A, Bloch K et al. Neutrophil adhesion molecule expression in familial Mediterranean fever: discordance between the intravascular regulation of beta2 integrin and L-selectin expression in acute attack. Jl Invest Med 2004;52:58–61.
17 Naegle M, Tillack K, Reinhardt S et al. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol 2012;242:60–71.
18 Ozen S, Uckan D, Baskin E et al. Increased neutrophil apoptosis during attacks of familial Mediterranean fever. Clin Exp Rheumatol 2001;19:568–71.
19 Ren Y, Tang J, Mok MY et al. Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus. Arthritis Rheum 2003;48:2888–97.
20 Bylund J, Brown KL, Movitz C, Dahlgren C, Karlsson A. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective degranulation, priming and apoptosis regulation. We conclude that our findings are in line with the hypothesis of normal neutrophil phenotype in SAPHO syndrome.
25 Lundqvist H, Dahlgren C. Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radical Biol Med 1996;20:785–92.

26 Christenson K, Thoren FB, Bylund J. Analyzing cell death events in cultured leukocytes. Methods Mol Biol 2012;844:65–86.

27 Zarember KA, Kuhns DB. Editorial: Will the real neutrophil please stand up? J Leukocyte Biol 2011;90:1039–41.

28 Qureshi SS, Lewis SM, Gant VA et al. Increased distribution and expression of CD64 on blood polymorphonuclear cells from patients with the systemic inflammatory response syndrome (SIRS). Clin Exp Immunol 2001;125:258–65.

29 Rosenbloom AJ, Pinsky MR, Bryant JL et al. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995;274:58–65.

30 Sundqvist M, Wekell P, Osla V et al. Increased intracellular oxygen radical production in neutrophils during febrile episodes of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. Arthritis Rheum 2013;65:2971–83.

31 Brown JR, Goldblatt D, Buddle J, Morton L, Thrasher AJ. Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD). J Leukocyte Biol 2003;73:591–9.

32 Kasahara Y, Iwai K, Yachie A et al. Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 1997;89:1748–53.

33 Tamayo E, Gomez E, Bustamante J et al. Evolution of neutrophil apoptosis in septic shock survivors and non-survivors. J Crit Care 2012;27:415e1–11.

34 Magrey M, Khan MA. New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome. Curr Rheumatol Reports 2009;11:329–33.

35 Assmann G, Simon P. The SAPHO syndrome--are microbes involved? Best Pract Res Clin Rheumatol 2011;25:423–34.

36 Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum 2009;61:813–21.

37 Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 1992;80:2012–20.

38 Condiffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci 1998;94:461–71.